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Depressive symptoms are a common, if under-researched and 
poorly understood, feature of schizophrenia. They can occur at 
any stage of the illness, with a reported prevalence of approxi-
mately 40% (Conley et al., 2007). Depressive symptoms can be 
important indicators of outcome; they contribute to suicidality, 
and relapse can follow a deterioration in depressive (but not 
positive or negative) symptoms (Tollefson et al., 1999). It is per-
haps unsurprising that low mood may be apparent in people 
experiencing unpleasant and frequently debilitating psychotic 
symptoms. Yet a depressed mood is more than just a conse-
quence of psychosis; depressive symptoms can, for example, 
occur prior to the manifestation of positive psychotic symp-
toms (Yung et al., 2004).
These symptoms are, by definition, equivalent those typic-
ally presenting in major depressive disorder. They can include 
the full gamut of features, including apathy and social with-
drawal as well as low mood, although some typical depressive 
symptoms such as weight loss or sleep disturbance may be con-
founded by drug treatment. It is also apparent that there may be 
overlap with the negative symptoms of schizophrenia, of which 
withdrawal and anhedonia are considered features. There is 
little to suggest that depressive symptoms of schizophrenia re-
spond to antidepressant augmentation of antipsychotic drug 
treatment, although it may be beneficial for negative symp-
toms (Galling et al., 2018). This observation can be interpreted 
in 2 ways: either the antipsychotic drugs themselves have anti-
depressant action making further intervention ineffective, or the 
depressive symptoms in schizophrenia are inherently different 
from those that respond to such treatment in major depression. 
There is certainly strong evidence for the former explanation.
It is clear that antipsychotic treatments may have anti-
depressant effects; several antipsychotic drugs are now also 
licensed for use in unipolar as well as bipolar depression. 
Second-generation antipsychotics (SGAs) have some efficacy 
in treatment-resistant depression (Zhou et  al., 2015); a recent 
Cochrane review indicated that augmentation of antidepressant 
therapy with cariprazine, olanzapine, quetiapine, or ziprasidone 
improved depressive symptoms in the short term (Davies et al., 
2019).
It is thus unsurprising that some antipsychotics may relieve 
the depressive symptoms of schizophrenia. The study by Miura 
et  al. (2020) addresses this with a meta-analysis of placebo-
controlled trials in which they demonstrated that most of the 
commonly used SGAs had efficacy in relieving depressive symp-
toms, while the 2 first-generation drugs, haloperidol and chlor-
promazine, showed no significant effect.
One anomaly was the result for ziprasidone, which they 
found had no significant influence on depressive symptoms 
over placebo. This may be a misleading finding reflective of the 
relatively small ziprasidone sample; the network meta-analysis 
of Huhn et al. (2019) suggests a significant if small effect in de-
pressive symptom improvement for ziprasidone, albeit signifi-
cantly weaker than olanzapine (and amisulpride and sulpiride, 
not assessed by Miura et  al., 2020) and similar to lurasidone. 
Some further findings from the Huhn et  al. (2019) analysis 
are worth contrasting with this study. Haloperidol was shown 
to be significantly more effective than placebo, which might 
argue against the conclusion that, of the antipsychotic drugs, 
it is only the SGAs that are effective in antidepressant action. 
Addington et al. (2011), in analyzing data from the CATIE study, 
also found no evidence for a class effect of SGAs by showing 
that perphenazine also had efficacy in ameliorating depressive 
symptoms.
What might be the underlying pharmacological basis of the 
antidepressant action of antipsychotic drugs? The 2 neurotrans-
mitter systems that have been most implicated in depression 
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and antidepressant response are those of serotonin and nor-
adrenaline. SGAs do not share with the antidepressant drugs an 
action in inhibiting serotonin or noradrenaline reuptake. They 
do, however, have effects at various receptors for these trans-
mitters, and it seems likely that such receptor effects are im-
portant in the antidepressant action of antipsychotic drugs.
There are several serotonin (5-hydroxytryptamine, 5-HT) 
receptors that may contribute to antidepressant activity. The 
5-HT2A site is a good candidate; antagonism of these recep-
tors, a feature of almost all SGAs, is thought to contribute to 
the ability of these drugs to augment the antidepressant effects 
of the SSRIs (Rogóż, 2013). However, this leaves unexplained the 
particular efficacy of amisulpride (Huhn et  al., 2019), an anti-
psychotic without 5-HT2A receptor affinity.
Thus, other receptors are likely to be involved in 
differentiating the antipsychotics in their antidepressant effi-
cacy. Two receptor mechanisms that may be important in this 
respect are alpha2 adrenergic receptor antagonism and 5-HT1A 
receptor partial agonism, both a feature of clozapine pharma-
cology. Antagonism of alpha2 adrenergic receptors increases 
synaptic serotonin and noradrenaline release, a presumed 
mode of action of the antidepressant mirtazapine, although the 
lack of efficacy of augmentation with this drug in relieving the 
depressive symptoms of schizophrenia (Kishi and Iwata, 2014), 
or in improving treatment-resistant depression as do some 
SGAs (Davies et al., 2019), might argue against this mechanism. 
However, an intriguing observation by Terevnikov et  al. (2015) 
points to a noradrenergic mechanism. Among the adjunctive 
antidepressants studied in schizophrenia, only “imipramine and 
duloxetine tended to improve depressive symptoms.” Both of 
these drugs block reuptake of noradrenaline as well as of sero-
tonin. While the antipsychotics themselves have no substantial 
effect on monoamine transmitter transporters, quetiapine’s 
major metabolite, norquetiapine, can inhibit noradrenergic re-
uptake (Cross et al., 2016), an effect likely to be clinically func-
tional (Yatham et al., 2018). Nevertheless, Miura et al. (2020) do 
not demonstrate any advantage of quetiapine over other SGAs.
The 5-HT1A receptors regulate serotonin neuronal activity, 
and partial agonist activity at this site is a feature of some, but 
not all, SGAs. Other serotonin receptors have also been impli-
cated, such as 5-HT7, at which amisulpride, lurasidone, and sev-
eral other SGAs are antagonists. However, activity at any one 
particular site does not obviously correlate with relative anti-
depressant efficacy. Furthermore, it is hard to ignore the possible 
contribution of dopamine D2 receptor mechanisms, common 
to all antipsychotic drugs, if an antidepressant action of anti-
psychotics is not specific to any pharmacologically defined 
subgroup. Certainly the dopamine system is implicated in de-
pression and antidepressant mechanisms. A rat model of stress-
induced depression is associated with reduced activity of limbic 
dopaminergic neurons; this can be normalized by repeated ad-
ministration of quetiapine at doses equivalent to those used for 
antidepressant treatment (Moreines et  al., 2017), although the 
underlying receptor mechanism remains elusive.
Further clues relating to these various pharmacological 
mechanisms may come from studies of factors contributing to 
individual variability. It is clear that depressive symptoms do not 
consistently improve in all people with schizophrenia following 
antipsychotic drug treatment; some respond well, whereas some 
respond poorly or even deteriorate. Genetic variability is likely to 
contribute to these inter-individual differences. Reflecting the 
general paucity of research into depressive symptoms in schizo-
phrenia, few pharmacogenetic studies have addressed their 
response to treatment. An early small investigation identified 
possible associations with genetic polymorphisms, including 
the alpha1A adrenoceptor and the 5-HT6 receptor (Houston 
et al., 2007); a larger study found association with a D2 receptor 
polymorphism (Misiak et  al., 2016). However, there have been 
other robust findings. The 5-HT1A receptor gene has a func-
tional polymorphism (rs6295) associated with depression and 
antidepressant response (Lemonde et al., 2004). A study of this 
polymorphism in antipsychotic drug response showed that it 
was associated, independently, with change in both negative 
and depressive symptoms in first-episode patients receiving 
risperidone or olanzapine (Reynolds et al., 2006). While the as-
sociation of rs6295 with negative symptom response has been 
observed in several further studies (Takekita et al., 2016), 1 re-
port has replicated this association with depressive symptom 
improvement with aripiprazole (Chen and Shen, 2017).
While these findings may tell us something about the biology 
underlying depressive, and negative, symptom response to 
treatment, they do indicate the lack of a clear biological dis-
tinction between the 2 symptom domains. This may be in part 
methodological; of the measures used for assessment of depres-
sive symptoms in schizophrenia, only the Calgary Depression 
Scale is designed to differentiate these from the negative symp-
toms. Thus, for many analyses using less specific scales, such 
as the Hamilton Depression Rating Scale, changes in negative 
symptoms may confound the findings (Addington et al., 1996). It 
is notable that the Montgomery-Åsberg Depression Rating Scale 
(MADRS) scale, on which depressive symptoms of schizophrenia 
have been assessed in several of the studies included in the 
meta-analysis of Miura et al. (2020) contains several items that 
could be considered negative symptoms; MADRS is found to cor-
relate with negative as well as depressive components of the 
Positive and Negative Syndrome Scale (Wolthaus et al., 2000).
However, depression in schizophrenia cannot be fully dif-
ferentiated from negative symptoms (Krynicki et  al., 2018). It 
may perhaps be worth considering that further attempts at the 
phenomenological division of distinct depressive and negative 
symptom domains might be less valuable than accepting they 
may have a common biological basis and that future research 
could benefit more from a search to understand the reasons 
why, for these symptoms, some patients respond better than 
others to drug treatments. Genetic studies provide just 1 ap-
proach towards this goal.
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